LNP delivery of mRNA & gene editors
Nanoparticle platforms for protein replacement, CRISPR-based editing, and cell engineering
Lipid nanoparticles are the leading non-viral vehicle for nucleic acid therapeutics, but most clinical LNPs still default to the liver and deliver only a fraction of their cargo. We engineer LNP formulations for mRNA, CRISPR-Cas ribonucleoproteins, and other gene editing payloads, combining formulation optimization, biophysical characterization of nanoparticle structure, and in vivo screening to improve potency and broaden the range of treatable tissues — from hepatic gene editing to T cell engineering.